Target- |
MechanismCytotoxic T lymphocytes stimulants [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with TriMed Biotech, Inc.
0 Patents (Medical) associated with TriMed Biotech, Inc.
100 Deals associated with TriMed Biotech, Inc.
100 Translational Medicine associated with TriMed Biotech, Inc.